Skip to main content

Enveric Biosciences Inc (ENVB) Stock

Enveric Biosciences Inc Stock Details, Movements and Public Alerts

Stock Details

Enveric Biosciences Inc (ENVB), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $4.08. Over the past 52 weeks, it has ranged between $3.50 and $66.58. This places the current price at 6.1% of its 52-week high and 16.6% above its 52-week low. 0The 14-day Relative Strength Index (RSI) stands at 43.70, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $5.29 by 22.87%. Similarly, it is below its 200-day moving average of $11.17 by 63.47%. The MACD histogram is 0.07, indicating bullish momentum (MACD Line: -0.47, Signal Line: -0.53). There is currently 1 active alert set for ENVB by users.

52-Week Range

$66.58 - $3.50

-93.87% from high · +16.57% from low

Avg Daily Volume

65,029

20-day average

100-day avg: 731,646

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

23.09

Price to Book

1.23

EV/EBITDA

0.29

EPS (TTM)

-$119.64

Price to Sales

0.08

Beta

0.28

Less volatile than market

Q:How is ENVB valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is ENVB's risk profile compared to the market?
With a beta of 0.28, Enveric Biosciences Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.23 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-9,675,295

Return on Equity

-262.00%

Return on Assets

-129.70%

Revenue Growth (YoY)

-7.30%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is ENVB's business model?
Profitability metrics are not available for this stock.
Q:What are ENVB's recent growth trends?
Enveric Biosciences Inc's revenue declined by 7.30% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$2.8M

Revenue (TTM)

$35.41M

Revenue/Share (TTM)

$37.68

Shares Outstanding

518.30K

Book Value/Share

$8.66

Asset Type

Common Stock

Q:What is ENVB's market capitalization and position?
Enveric Biosciences Inc has a market capitalization of $2.8M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 518.30K shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does ENVB's price compare to its book value?
Enveric Biosciences Inc's book value per share is $8.66, while the current stock price is $4.08, resulting in a price-to-book (P/B) ratio of 0.47. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$10.00

145.10% upside potential

Analyst Recommendations

No analyst ratings available

Q:How reliable are analyst predictions for ENVB?
0 analysts cover ENVB with 0% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $10.00 implies 145.1% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on ENVB?
Current analyst recommendations:The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jan 16, 2026, 02:02 AM

Technical Indicators

RSI (14-day)

43.70

Neutral

50-Day Moving Average

$5.29

-22.87% below MA-50

200-Day Moving Average

$11.17

-63.47% below MA-200

MACD Line

-0.47

MACD Signal

-0.53

MACD Histogram

0.07

Bullish

Q:What does ENVB's RSI value tell investors?
The RSI (Relative Strength Index) for ENVB is currently 43.70, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret ENVB's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.47 above the signal line at -0.53, with histogram at 0.07. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($5.29) is below the 200-day MA ($11.17), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Jan 16, 2026, 12:36 AM

Active Alerts

Alert Condition
Volume change
Threshold
25%
Created
Jan 7, 2026, 05:36 PM

Stay Ahead of the Market with Enveric Biosciences Inc Alerts

Set up price alerts for Enveric Biosciences Inc and get notified instantly when the price hits your target. Never miss an important price movement again.